^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

NY-ESO-1 Iscomatrix

i
Other names: NY-ESO-1 Iscomatrix
Associations
Company:
CSL Behring, Ludwig Institute for Cancer Research
Drug class:
Immunostimulant
Related drugs:
Associations
3years
Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies. (PubMed, Transl Lung Cancer Res)
Eight of 14 patients (57%) exhibited serologic responses to NY-ESO-1. Cyclophosphamide/celecoxib did not appear to increase immune responses or enhance vaccine-induced alterations in peripheral immune subsets. H1299 lysate vaccines with Iscomatrix™ induce immune responses to CTA and modulate peripheral immune subsets in a manner that may enhance antitumor immunity in patients with thoracic malignancies.
Clinical • P1 data • P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTAG1B (Cancer/testis antigen 1B) • CD14 (CD14 Molecule)
|
PD-L1 expression • PD-1 expression
|
H1299 cell lysate with iscomatrix adjuvant vaccine • NY-ESO-1 Iscomatrix • celecoxib oral
4years
Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer. (PubMed, Cancer Immunol Immunother)
NK cells, CD4 T cells and interferon-γ were all found to be critical for tumor control while tumor infiltrating CD8 T cells became disabled by an immunosuppressive microenvironment. There is potential for broader application of this cancer vaccine, as we have been able to demonstrate effectiveness in two additional cancer models; melanoma (B16-OVA) and a model of B cell lymphoma (Eµ-myc-GFP-OVA).
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • CD8 (cluster of differentiation 8)
|
NY-ESO-1 Iscomatrix
over4years
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. (PubMed, J Immunother Cancer)
The vaccine was well tolerated, however, despite inducing antigen-specific immunity, it did not affect survival endpoints. Immune escape through the downregulation of NY-ESO-1 and/or HLA class I molecules on tumor may have contributed to relapse.
Clinical • P2 data • Journal
|
CD8 (cluster of differentiation 8)
|
NY-ESO-1 Iscomatrix
over4years
Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review. (PubMed, Arch Virol)
Adjuvants have various functions, especially in therapeutic vaccines, and they lead to an increase in cytotoxic T lymphocytes (CTLs), so they are important in the design of vaccines. Here, we review the currently used adjuvants and their combinations with HPV protein vaccines in order to introduce an appropriate adjuvant for HPV vaccines.
Review • Journal
|
IL2 (Interleukin 2) • CSF2 (Colony stimulating factor 2)
|
NY-ESO-1 Iscomatrix